18F-FDG ( DrugBank: 18F-FDG )
8 diseases
告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
5 | 進行性核上性麻痺 | 1 |
6 | パーキンソン病 | 5 |
7 | 大脳皮質基底核変性症 | 1 |
13 | 多発性硬化症/視神経脊髄炎 | 1 |
84 | サルコイドーシス | 2 |
85 | 特発性間質性肺炎 | 1 |
127 | 前頭側頭葉変性症 | 1 |
300 | IgG4関連疾患 | 1 |
5. 進行性核上性麻痺
臨床試験数 : 89 / 薬物数 : 107 - (DrugBank : 40) / 標的遺伝子数 : 65 - 標的パスウェイ数 : 108
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | JPRN-UMIN000036908 | 2019/05/31 | 31/05/2019 | A dementia study by 11C-PiB, 18F-FDG PET | A dementia study by 11C-PiB, 18F-FDG PET - A dementia study by 11C-PiB, 18F-FDG PET | mild cognitive impairment, Alzheimer's disease, dementia with Lewy bodies, cerebrovascular dementia, frontotemporal degeneration, progressive supranuclear palsy, corticobasal degeneration, Parkinson's disease with dementia, other neurodegenerative diseases, normal pressure hydrocephalus, hypoxic encephalopathy, brain tumor, brain injury etc. | 11C-PiB, 18F-FDG PET | Nagoya City Rehabilitation Agency | NULL | Recruiting | 20years-old | Not applicable | Male and Female | 150 | Not applicable | Japan |
6. パーキンソン病
臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | ChiCTR2000036137 | 2020-10-01 | 2020-08-21 | Clinical study of 18F-FDG combined with 18F-AV-133 PET/CT imaging in the diagnosis and differentiation of primary Parkinson's disease | Clinical study of 18F-FDG combined with 18F-AV-133 PET/CT imaging in the diagnosis and differentiation of primary Parkinson's disease | Parkinson’s disease | Gold Standard:UK Parkinson's disease Society Brain Bank Clinical Diagnosis Criteria;Index test:18F-FDG combined with 18F-AV-133 PET/CT imaging; | Renji Hospital (South Court), School of Medicine, Shanghai Jiao Tong University | NULL | Pending | Both | Target condition:50;Difficult condition:0 | China | |||
2 | ChiCTR2000037856 | 2020-10-01 | 2020-09-02 | Detection of A-synuclein Aggregate as Biomarker in Diagnosing Parkinson's Disease at Early Stage by Using Protein Misfolding Cyclic Amplification (PMCA) | Detection of A-synuclein Aggregate as Biomarker in Diagnosing Parkinson's Disease at Early Stage by Using Protein Misfolding Cyclic Amplification (PMCA) | Parkinson's Disease | Gold Standard:DAT-PET and 18F-FDG PET ;Index test:a-synuclein protein misfolding cyclic amplification; | Huashan Hospital Affiliated to Fudan University | NULL | Recruiting | 50 | 75 | Both | Target condition:150;Difficult condition:76 | China | |
3 | JPRN-UMIN000036908 | 2019/05/31 | 31/05/2019 | A dementia study by 11C-PiB, 18F-FDG PET | A dementia study by 11C-PiB, 18F-FDG PET - A dementia study by 11C-PiB, 18F-FDG PET | mild cognitive impairment, Alzheimer's disease, dementia with Lewy bodies, cerebrovascular dementia, frontotemporal degeneration, progressive supranuclear palsy, corticobasal degeneration, Parkinson's disease with dementia, other neurodegenerative diseases, normal pressure hydrocephalus, hypoxic encephalopathy, brain tumor, brain injury etc. | 11C-PiB, 18F-FDG PET | Nagoya City Rehabilitation Agency | NULL | Recruiting | 20years-old | Not applicable | Male and Female | 150 | Not applicable | Japan |
4 | ChiCTR-DDD-16009569 | 2017-01-01 | 2016-10-24 | Differential diagnosis of primary Parkinson's disease by 18F-FDG combined with 11C-ß-CFT PET / CT imaging | Differential diagnosis of primary Parkinson's disease by 18F-FDG combined with 11C-ß-CFT PET / CT imaging | Parkinson's Disease | Gold Standard:;Index test:; | Renji hospital, School of Medicine, Shanghai Jiao Tong University | NULL | Pending | 20 | 80 | Both | Target condition:0;Difficult condition:0 | China | |
5 | NCT01824056 (ClinicalTrials.gov) | August 2010 | 12/3/2013 | The Differential Diagnosis of Parkinson's Disease and Parkinsonism by Positron-emission Tomography | The Differential Diagnosis of Parkinson's Disease and Parkinsonism by Positron-emission Tomography With Vesicular Monoamine Transporter Ligand (18F-DTBZ) | Parkinson's Disease | Drug: 18F-FDG | Chang Gung Memorial Hospital | National Science Council, Taiwan | Completed | 20 Years | 80 Years | Both | 120 | Phase 2 | Taiwan |
7. 大脳皮質基底核変性症
臨床試験数 : 16 / 薬物数 : 28 - (DrugBank : 13) / 標的遺伝子数 : 9 - 標的パスウェイ数 : 38
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | JPRN-UMIN000036908 | 2019/05/31 | 31/05/2019 | A dementia study by 11C-PiB, 18F-FDG PET | A dementia study by 11C-PiB, 18F-FDG PET - A dementia study by 11C-PiB, 18F-FDG PET | mild cognitive impairment, Alzheimer's disease, dementia with Lewy bodies, cerebrovascular dementia, frontotemporal degeneration, progressive supranuclear palsy, corticobasal degeneration, Parkinson's disease with dementia, other neurodegenerative diseases, normal pressure hydrocephalus, hypoxic encephalopathy, brain tumor, brain injury etc. | 11C-PiB, 18F-FDG PET | Nagoya City Rehabilitation Agency | NULL | Recruiting | 20years-old | Not applicable | Male and Female | 150 | Not applicable | Japan |
13. 多発性硬化症/視神経脊髄炎
臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02305264 (ClinicalTrials.gov) | March 19, 2012 | 25/1/2013 | Imaging of Intracerebral Inflammation in MS | Imaging of Intracerebral Inflammation in the Progressive Phase of Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting;Multiple Sclerosis, Secondary Progressive;Multiple Sclerosis, Primary Progressive | Drug: 18F-DPA-714 and 18F-FDG | Assistance Publique - Hôpitaux de Paris | NULL | Completed | 18 Years | 65 Years | All | 61 | N/A | France |
84. サルコイドーシス
臨床試験数 : 149 / 薬物数 : 202 - (DrugBank : 78) / 標的遺伝子数 : 66 - 標的パスウェイ数 : 169
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03705884 (ClinicalTrials.gov) | January 1, 2018 | 8/8/2018 | PET/MR Imaging In Patients With Cardiac Sarcoidosis | Molecular Imaging in Cardiovascular Disease Using Hybrid Positron Emission Tomography/Magnetic Resonance Imaging (PET/MR): Cardiac Sarcoidosis | Cardiac Sarcoidosis | Other: 18F-FDG;Drug: Prednisolone | University of Edinburgh | NULL | Unknown status | 40 Years | N/A | All | 40 | N/A | United Kingdom |
2 | JPRN-UMIN000004267 | 2010/10/01 | 01/10/2010 | PET/CT finding of cardiac sarcoidosis | PET/CT finding of cardiac sarcoidosis - PET/CT finding of cardiac sarcoidosis | sarcoidosis | Give heparin Na before 18F-FDG PET/CT in the diagnosis of cardial sarcoidosis. | Tokushima University Hospital | NULL | Pending | Not applicable | Not applicable | Male and Female | 30 | Not selected | Japan |
85. 特発性間質性肺炎
臨床試験数 : 627 / 薬物数 : 443 - (DrugBank : 120) / 標的遺伝子数 : 99 - 標的パスウェイ数 : 212
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | JPRN-UMIN000010498 | 2007/10/01 | 15/04/2013 | Prognostic Value of Dual-time-point 18F-FDG PET in Fibrotic Idiopathic Interstitial Pneumonia | Prognostic Value of Dual-time-point 18F-FDG PET in Fibrotic Idiopathic Interstitial Pneumonia - Prognostic Value of Dual-time-point 18F-FDG PET in Fibrotic Idiopathic Interstitial Pneumonia | Idiopathic interstital pneumonia | All patients with idiopathic interstitial pneumonia undergo dual-time-point 18F-FDG PET of thorax. | Third Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui | Biomedical Imaging Research Center, Faculty of Medical Sciences, Universtity of Fukui | Complete: follow-up complete | 18years-old | Not applicable | Male and Female | 80 | Not applicable | Japan |
127. 前頭側頭葉変性症
臨床試験数 : 90 / 薬物数 : 87 - (DrugBank : 30) / 標的遺伝子数 : 39 - 標的パスウェイ数 : 88
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01890343 (ClinicalTrials.gov) | September 2009 | 27/6/2013 | Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls. | A Study Evaluating the Imaging Characteristics of Florbetapir 18F (18F-AV-45) in Patients With Frontotemporal Dementia Compared to Patients With Alzheimer's Disease and Normal Controls. | Alzheimer's Disease;Frontotemporal Dementia | Drug: florbetapir 18F;Drug: 18F-FDG | Avid Radiopharmaceuticals | NULL | Completed | 45 Years | N/A | All | 34 | Phase 2 | United Kingdom |
300. IgG4関連疾患
臨床試験数 : 40 / 薬物数 : 47 - (DrugBank : 21) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 141
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01665196 (ClinicalTrials.gov) | September 2012 | 13/8/2012 | 18F-FDG PET/CT for IgG4-Related Disease | Evaluation of 18F-FDG PET/CT in Diagnosis and Response Assessment of Patients With IgG4-Related Disease | Autoimmune Disease | Drug: 18F-FDG | Peking Union Medical College Hospital | NULL | Recruiting | 18 Years | 75 Years | All | 100 | Early Phase 1 | China |